Metropolitan Life Insurance CO Rubius Therapeutics, Inc. Transaction History

Metropolitan Life Insurance CO

$253 Million
Q2 2024

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$0.79 - $5.98 $2,496 - $18,896	-3,160 Closed	0 $0
Q1 2022 Jun 20, 2023	BUY	$4.25 - $10.4 $13,430 - $32,864	3,160 New	3,160 $17,000
Q1 2022 Mar 30, 2023	SELL	$4.25 - $10.4 $39,095 - $95,669	-9,199 Reduced 74.43%	3,160 $17,000
Q1 2022 May 12, 2022	SELL	$4.25 - $10.4 $39,095 - $95,669	-9,199 Reduced 74.43%	3,160 $17,000
Q4 2021 Jun 21, 2023	BUY	$9.68 - $17.74 $119,635 - $219,248	12,359 New	12,359 $119,000
Q4 2021 Mar 30, 2023	SELL	$9.68 - $17.74 $4,539 - $8,320	-469 Reduced 3.66%	12,359 $119,000
Q4 2021 Feb 15, 2022	SELL	$9.68 - $17.74 $4,539 - $8,320	-469 Reduced 3.66%	12,359 $120,000
Q3 2021 Jun 21, 2023	BUY	$17.6 - $25.91 $225,772 - $332,373	12,828 New	12,828 $229,000
Q2 2021 Jun 21, 2023	BUY	$22.26 - $28.43 $285,551 - $364,700	12,828 New	12,828 $313,000
Q2 2021 Mar 30, 2023	BUY	$22.26 - $28.43 $58,321 - $74,486	2,620 Added 25.67%	12,828 $313,000
Q2 2021 Aug 16, 2021	BUY	$22.26 - $28.43 $285,328 - $364,415	12,818 Added 128180.0%	12,828 $313,000
Q1 2021 Jun 26, 2023	BUY	$8.02 - $32.01 $81,868 - $326,758	10,208 New	10,208 $271 Million
Q1 2021 Mar 30, 2023	SELL	$8.02 - $32.01 $15,286 - $61,011	-1,906 Reduced 15.73%	10,208 $270,000
Q1 2021 May 14, 2021	BUY	$8.02 - $32.01 $80 - $320	10 New	10 $271,000
Q3 2020 Nov 13, 2020	SELL	$4.65 - $6.25 $56,330 - $75,712	-12,114 Closed	0 $0
Q2 2020 Jun 26, 2023	BUY	$4.01 - $6.88 $48,577 - $83,344	12,114 New	12,114 $72,000
Q2 2020 Mar 30, 2023	BUY	$4.01 - $6.88 $5,858 - $10,051	1,461 Added 13.71%	12,114 $72,000
Q2 2020 Aug 14, 2020	BUY	$4.01 - $6.88 $48,577 - $83,344	12,114 New	12,114 $72,000
Q1 2020 May 15, 2020	SELL	$3.74 - $9.84 $39,842 - $104,825	-10,653 Closed	0 $0
Q4 2019 Jul 12, 2023	BUY	$7.23 - $14.12 $77,021 - $150,420	10,653 New	10,653 $101,000
Q4 2019 Mar 30, 2023	SELL	$7.23 - $14.12 $8,777 - $17,141	-1,214 Reduced 10.23%	10,653 $101,000
Q4 2019 Feb 14, 2020	SELL	$7.23 - $14.12 $8,777 - $17,141	-1,214 Reduced 10.23%	10,653 $101,000
Q3 2019 Jul 12, 2023	BUY	$7.85 - $15.75 $93,155 - $186,905	11,867 New	11,867 $93,000
Q2 2019 Jul 12, 2023	BUY	$13.5 - $19.94 $160,204 - $236,627	11,867 New	11,867 $186,000
Q1 2019 Jul 13, 2023	BUY	$13.27 - $18.51 $157,475 - $219,658	11,867 New	11,867 $214,000
Q1 2019 Mar 30, 2023	BUY	$13.27 - $18.51 $157,475 - $219,658	11,867 New	11,867 $214,000
Q1 2019 May 16, 2019	BUY	$13.27 - $18.51 $102,815 - $143,415	7,748 Added 188.1%	11,867 $214,000
Q1 2019 May 15, 2019	SELL	$13.27 - $18.51 $40,765 - $56,862	-3,072 Reduced 42.72%	4,119 $1.21 Million
Q4 2018 Jul 13, 2023	BUY	$13.83 - $22.97 $99,451 - $165,177	7,191 New	7,191 $115,000
Q4 2018 Feb 14, 2019	BUY	$13.83 - $22.97 $75,802 - $125,898	5,481 Added 320.53%	7,191 $116,000
Q3 2018 Jul 13, 2023	BUY	$20.06 - $26.94 $156,648 - $210,374	7,809 New	7,809 $187 Million
Q3 2018 Nov 14, 2018	BUY	$20.06 - $26.94 $34,302 - $46,067	1,710 New	1,710 $41,000

Others Institutions Holding RUBY

# of Institutions

Shares Held

325

Call Options Held

Put Options Held

American Portfolios Advisors Holbrook, NY

325
Shares

$0
0.0% of portfolio
Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

View Full List

About Rubius Therapeutics, Inc.

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

More about RUBY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.

Account